Hehehe!!! That is the ABSOLUTE PURPOSE OF ORPHAN DESIGNATION:-)
That is why RUBINFELD was brought as one of the advisors because he is the ARCHITECT OF BIOTECH COMPANIES in the world.
Read his ACHIEVEMENTS in AMGEN and specifically SUPERGEN!
SUPERGEN is an excellent model for AMBS!!!
One product will not be an absolute buyout / partnership!!!
RUBIN made his map on AMBS recommending several products in MID or late stage drug development to COMPLIMENT MANF. In addition our diagnostic product will make AMBS a VIABLE AND REAL TARGET FOR A PARTNERSHIP & BUYOUT CANDIDATE in the future.
Get ready for LEVODOPA ??? LOI was drafted, waiting for due diligence and favorable terms :-)
Remember AMBS IS A HOLDING COMPANY NOW. VERY attractive for M&A .
Market Data 
Markets 
AI
